Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05763576 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT05763576 is a Phase 1 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 60 participants.
The verdict
NCT05763576, a Phase 1 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is a first in human (FIH), multi-center, dose-finding, and dose-escalation Phase I clinical study of RO7565020 to investigate the safety and tolerability and to characterize the pharmacokinetics and pharmacodynamics following single and/or multiple doses of RO7565020 in healthy participants and/or virologically suppressed participants with chronic hepatitis B (CHB).
Interventions
- OTHER Placebo
- DRUG RO7565020
- DRUG Nucleos(t)ide analogue (NUC) treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-04-28 |
| Est. Completion | 2024-12-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05763576
The ClinicalTrials.gov registry entry for NCT05763576 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05763576 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05763576 about?
NCT05763576 is a clinical study titled "A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection". This is a first in human (FIH), multi-center, dose-finding, and dose-escalation Phase I clinical study of RO7565020 to investigate the safety and tolerability and to characterize the pharmacokinetics and pharmacodynamics following single and/or multiple doses of RO7565020 in healthy participants and...
What is the current status of trial NCT05763576?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-04-28. Estimated completion is 2024-12-23.
What interventions are being tested in trial NCT05763576?
The interventions under investigation include: Placebo (OTHER), RO7565020 (DRUG), Nucleos(t)ide analogue (NUC) treatment (DRUG).
Who is sponsoring clinical trial NCT05763576?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.